Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Tolisign
- Development stage
- Unknown
- Lead developer
- Primus Remedies
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Tolisign is a brand name owned by Primus Remedies for a line of combination oral therapies containing the centrally acting muscle relaxant tolperisone. The product line includes Tolisign-P, a fixed-dose combination of tolperisone (150 mg) and paracetamol (325 mg), and Tolisign-D, a fixed-dose combination of tolperisone (150 mg) and diclofenac (50 mg). Tolperisone acts as a muscle relaxant by blocking voltage-gated sodium and calcium channels in the spinal cord and brainstem, thereby inhibiting mono- and polysynaptic spinal reflexes. Paracetamol and diclofenac provide analgesic and anti-inflammatory effects by inhibiting cyclooxygenase (COX) enzymes (prostaglandin G/H synthases). These combinations are indicated for the treatment of painful muscle spasms and acute musculoskeletal conditions.
- Brand names
- Tolisign-DTolisign-P
- Other names
- diclofenac + tolperisoneparacetamol + tolperisoneTolisign-DTolisign-P
02
Targets
PGHS-1 (Prostaglandin G/H Synthase 1)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)CaV (Voltage-gated calcium channel protein complex)NaV (Voltage-gated sodium channels)
Beyond the preview
Go deeper on Tolisign.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Tolisign.